Search for: "Octapharma USA, Inc"
Results 1 - 1
of 1
Sorted by Relevance
|
Sort by Date
8 Aug 2012, 8:40 pm
FDA-2011-P-0213) CSL Behring (“CSL”) submitted to FDA in March 2011 requesting that the Agency: (1) revoke the orphan drug designation and the period of orphan drug exclusivity FDA subsequently granted to Octapharma USA, Inc. [read post]
